Should Osimertinib Become First-Line Treatment of Choice for EGFR Mutation-Positive Advanced NSCLC, or Should it Be Saved for Later? (BMIC-017) - 102204

Spotlight
Video

Should Osimertinib Become First-Line Treatment of Choice for EGFR Mutation-Positive Advanced NSCLC, or Should it Be Saved for Later? (BMIC-017)

BeaconMedIC has 63 videos Subscribe Here

Loading........
Description: Dr. Jack West reviews the pros and cons of using osimertinib first line vs. "saving" it as a second line therapy, trying to determine the optimal sequence for EGFR-directed therapy in advanced EGFR mutation-positive NSCLC.
Shared By : BeaconMedIC
Posted on : 12/01/17
Added : 10 months ago